Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print January 10, 2007, doi:10.1212/01.wnl.0000250332.89420.e6)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000250332.89420.e6v1
68/9/643    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in Neurology
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dombi, E.
Right arrow Articles by Widemann, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dombi, E.
Right arrow Articles by Widemann, B. C.
NEUROLOGY 2007;68:643-647
© 2007 American Academy of Neurology

NF1 plexiform neurofibroma growth rate by volumetric MRI

Relationship to age and body weight

E. Dombi, MD, J. Solomon, PhD, A. J. Gillespie, RNMS, E. Fox, MD, F. M. Balis, MD, N. Patronas, MD, B. R. Korf, MD, PhD, D. Babovic-Vuksanovic, MD, R. J. Packer, MD, J. Belasco, MD, S. Goldman, MD, R. Jakacki, MD, M. Kieran, MD, S. M. Steinberg, PhD and B. C. Widemann, MD

From the Pediatric Oncology Branch (E.D., A.J.G., E.F., F.M.B., B.C.W.), NCI, Bethesda, MD; Medical Numerics, Inc. (J.S.), Sterling, VA; Diagnostic Radiology Department (N.P.), National Institutes of Health, Clinical Center, Bethesda, MD; University of Alabama at Birmingham (B.R.K.), Birmingham, AL; Mayo Clinic (D.B.-V.), Rochester, MN; Children’s National Medical Center (R.J.P.), Washington, DC; Children’s Hospital of Philadelphia (J.B.), Philadelphia, PA; Children’s Memorial Hospital (S.G.), Chicago, IL; Children’s Hospital of Pittsburgh (R.J.), Pittsburgh, PA; Dana Farber Cancer Institute (M.K.), Boston, MA; and Biostatistics and Data Management Section (S.M.S.), CCR, National Cancer Institute, Bethesda, MD.

Address correspondence and reprint requests to Dr. Eva Dombi, Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 CRC, Room 1-5750, MSC 1101, Bethesda, MD 20892; e-mail: dombie{at}mail.nih.gov

Objective: To longitudinally analyze changes in plexiform neurofibroma (PN) volume in relation to age and body growth in children and young adults with neurofibromatosis type 1 and inoperable, symptomatic, or progressive PNs, using a sensitive, automated method of volumetric MRI analysis.

Methods: We included patients 25 years of age and younger with PNs entered in a natural history study or in treatment trials who had volumetric MRI over ≥16 months.

Results: We studied 49 patients (median age 8.3 years) with 61 PNs and a median evaluation period of 34 months (range 18 to 70). The PN growth rates varied among patients, but were constant within patients. Thirty-four patients (69%) experienced ≥20% increase in PN volume during the observation period. PN volume increased more rapidly than body weight over time (p = 0.026). Younger patients had the most rapid PN growth rate.

Conclusions: Volume increase of plexiform neurofibromas is a realistic and meaningful trial endpoint. In most patients plexiform neurofibroma growth rate exceeded body growth rate. The youngest patients had the fastest plexiform neurofibroma growth rate, and clinical drug development should be directed toward this population. Age stratification for clinical trials for plexiform neurofibromas should be considered.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the February 27 issue to find the title link for this article.

Commentary, see page 627

This article was previously published in electronic format as an Expedited E-Pub on January 10, 2007, at www.neurology.org.

This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This research was also supported by the U.S. Army through three clinical trial awards: 1) natural history of plexiform neurofibromas in NF1, grant no. NF70002; 2) phase II randomized, cross-over, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor R115777 in pediatric patients with neurofibromatosis type 1 and progressive plexiform neurofibromas, grant no. NF000027; 3) phase I/phase II study of pirfenidone in NF1 and plexiform neurofibromas, grant no. NF010042.

Disclosure: The authors report no conflicts of interest.

Received March 21, 2006. Accepted in final form July 21, 2006.


Related articles in Neurology:

February 27 Highlight and Commentary: Volumetric MRI sensitively measures plexiform neurofibroma growth in NF1

Neurology 2007 68: 627. [Full Text]  



This article has been cited by other articles:


Home page
 Neuro OncolHome page
V.-F. Mautner, F. A. Asuagbor, E. Dombi, C. Funsterer, L. Kluwe, R. Wenzel, B. C. Widemann, and J. M. Friedman
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
Neuro-oncol, August 1, 2008; 10(4): 593 - 598.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.